JILIN AODONG(SZ:000623) Sou Hu Cai Jing·2025-08-08 11:58Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a significant increase in net profit despite a decrease in total revenue for the first quarter of 2025, indicating potential resilience in profitability amidst revenue challenges [1]. Financial Performance - As of the first quarter of 2025, the company achieved total revenue of 623 million yuan, a year-on-year decrease of 27.71% [1]. - The net profit attributable to shareholders was 517 million yuan, reflecting a year-on-year increase of 259.75% [1]. - The non-recurring net profit was 488 million yuan, showing a year-on-year growth of 75.56% [1]. - The current ratio was reported at 1.871, the quick ratio at 1.525, and the debt-to-asset ratio at 11.43% [1]. Market Activity - As of August 8, 2025, the stock price closed at 19.15 yuan, with a slight increase of 0.21% [1]. - The trading volume was 138,700 hands, with a total transaction amount of 266 million yuan [1]. - There was a net outflow of main funds amounting to 19.09 million yuan, which accounted for 7.18% of the transaction amount [1]. Company Background - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1993 and is located in Yanbian Korean Autonomous Prefecture, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 11,958.95387 million yuan and a paid-in capital of the same amount [1]. - The legal representative of the company is Li Xiulin [1]. Investment and Intellectual Property - The company has made investments in 47 enterprises and participated in one bidding project [2]. - It holds 216 trademark registrations and 8 patents, along with 3 administrative licenses [2].